Genmab A/S Files June 2024 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Jun 10, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
Related Tickers: GMAB
TL;DR
Genmab filed a 6-K on 6/10/24, incorporating it into existing S-8 filings.
AI Summary
Genmab A/S filed a Form 6-K on June 10, 2024, to report information for the month of June 2024. This report is incorporated by reference into Genmab's existing S-8 registration statements, which relate to employee stock plans.
Why It Matters
This filing serves as an update for Genmab A/S, potentially containing information relevant to investors regarding its ongoing operations or corporate actions.
Risk Assessment
Risk Level: low — This filing is a routine report and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-009032 (filing_id) — Accession Number
- 20240610 (date) — Filing Date
- 333-232693, 333-253519, 333-262970 and 333-277273 (filing_id) — S-8 Registration Statements
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information to the SEC.
What is the filing date of this Form 6-K?
This Form 6-K was filed on June 10, 2024.
What is the company filing this report?
The company filing this report is Genmab A/S.
How is this filing related to Genmab's registration statements?
This Form 6-K is deemed to be incorporated by reference into Genmab A/S's registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2024-06-10 12:51:25
Filing Documents
- tmb-20240610x6k.htm (6-K) — 22KB
- tmb-20240610xex99d1.htm (EX-99.1) — 66KB
- tmb-20240610xex99d1a.htm (EX-99.1(A)) — 2091KB
- tmb-20240610xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240610xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-009032.txt ( ) — 2194KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: JUNE 10, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated June 10, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix Share buyback program – Specification for June 3 – June 7, 2024